COVID-19 Update on Recombinant Hirudin Medicine Market Revenue and Cost Overview 2020-2026 by Manufacturers Teva Pharmaceutical, Pfizer, Pentapharm -…

Posted on by

The Global Recombinant Hirudin Medicine Market is growing at a quicker pace with substantial growth rates over the previous few years and is calculable that the market can grow considerably within the forecasted period 2020-2026. Global Recombinant Hirudin Medicine Market Depth Analysis 2020-2026 could be a wide-ranging analysis of growth factors covering provincial openings, application landscape, product demand trends and end-use portfolio of the Recombinant Hirudin Medicine industry. The report conjointly outlines the competitive structure of the Recombinant Hirudin Medicine industry particularisation the analysis and Recombinant Hirudin Medicine market share dominance of the distinguished manufacturers.

Access Free Sample Copy of Recombinant Hirudin Medicine Market Report

The Global Recombinant Hirudin Medicine Market report provides a holistic analysis of the marketplace for the forecast period 2020-2026. The report includes of assorted segments still Associate in Nursing analysis of the trends and factors that square measure taking part in a considerable role within the market. These factors; the market dynamics, involves the drivers, restraints, opportunities and challenges through that the impact of those factors within the market square measure printed. The drivers and restraints square measure intrinsic factors whereas opportunities and challenges square measure foreign factors of the market. the world Recombinant Hirudin Medicine Market study provides Associate in Nursing outlook on the event of market in terms of revenue throughout the prognosis period.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

As we have a tendency to square measure within the marketing research industry since previous few years dedicated towards providing valuable insights of Recombinant Hirudin Medicine Market to business skilled, industry specialists, call manufacturers, Market adviser and different businesses. Global Recombinant Hirudin Medicine Market report is an in depth analysis of all obtainable corporations with their growth factors, analysis & methodology, Recombinant Hirudin Medicine Market Dynamics, Business summary, Sales, Revenue, Recombinant Hirudin Medicine Market Share and Competition with different makers.

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert

Global Major Market Players indulged in this report are:

AbbottThe Medicines CompanyTeva PharmaceuticalPfizerPentapharm

The Recombinant Hirudin Medicine Market report is segmented into following categories:

The Recombinant Hirudin Medicine market report is segmented into Type by following categories;12000 ATU / mg16000 ATU / mg16000 ATU / mgOthers

The Recombinant Hirudin Medicine market report is segmented into Application by following categories;Thrombosis DiseaseTumor DiseaseOthers

This report provides an all-inclusive environment of the study for the world Recombinant Hirudin Medicine Market. The market estimates provided within the report are the results of in-depth secondary analysis, primary interviews and in-house knowledgeable reviews. These market estimates are thought-about by learning the impact of assorted social, political and economic factors in conjunction with the present market dynamics moving the world Recombinant Hirudin Medicine Market rate.

Along with the market summary, that includes of the market dynamics the chapter includes a Porters 5 Forces analysis that explains the 5 forces: specifically patrons talks power, suppliers talks power, threat of recent entrants, threat of substitutes and degree of competition within the Worldwide Recombinant Hirudin Medicine Market. It explains the varied participants, like system integrators, intermediaries and end-users inside the scheme of the market. The report conjointly focuses on the competitive landscape of the world Recombinant Hirudin Medicine Market 2020-2026.

Checkout FREE Report Sample of Recombinant Hirudin Medicine Market Report for Better Understanding

The market research entails a locality alone dedicated for major manufacturers within the Worldwide Recombinant Hirudin Medicine Market whereby our analysts give an insight to the monetary statements of all the key manufacturers in conjunction with its key developments product benchmarking and SWOT analysis. the corporate profile section conjointly includes a business summary and monetary data. the businesses that square measure provided during this section will be custom-built in line with the clients necessities.

Also, this report discusses the key drivers influencing Recombinant Hirudin Medicine market growth, opportunities, the challenges and therefore the risks faced by key manufacturers and therefore the market. It conjointly analyzes key rising trends and their impact on present and future development methodology.

Global Recombinant Hirudin Medicine Market Research Report 2020-2026 Provides Comprehensive Depth Analysis as Following:

Global Recombinant Hirudin Medicine Market segments and sub-segments.Global Recombinant Hirudin Medicine Market size, shares, trends and dynamics.Global Recombinant Hirudin Medicine Market Competitive landscape, offer and demand.Technological inventions in Worldwide Recombinant Hirudin Medicine industry.Global Recombinant Hirudin Medicine Market, promoting Channel Development Trend.Global Recombinant Hirudin Medicine Market rating Strategy, whole Strategy, Target consumer.Global Recombinant Hirudin Medicine Market Distributors/industryrs List.

See the original post here:

COVID-19 Update on Recombinant Hirudin Medicine Market Revenue and Cost Overview 2020-2026 by Manufacturers Teva Pharmaceutical, Pfizer, Pentapharm -...

Family Medicine Is Key to Her Career in Global Health – AAFP News

Posted on by

After graduating from Princeton University with an undergraduate degree in anthropology, Erin Ferenchick, M.D., spent a year as a fellow for Princeton in Africa,(www.princetoninafrica.org) performing needs assessments, securing grants and supporting project implementation to address important issues like maternal-child health for the International Rescue Committee in Somaliland. She then spent two years as executive director of PiAf, which offers fellowships in public health, education, conservation, social entrepreneurship and microfinance.

"I enjoyed the work, but I realized I needed a more solid and tailored technical skill set to contribute in a sustainable and impactful way, so I went to medical school," Ferenchick said. "I chose family medicine because it gave me the broadest skill set, was the specialty most focused both on the patient and the broader community, and allowed me to leverage a career in global health. I've tried to keep one foot in the clinical world and one foot in global health, which is more focused on policy and programming. It's not always an easy balance to meet."

Ferenchick's clinical role is as an assistant clinical professor of medicine in the Center for Family and Community Medicine at her alma mater, Columbia University Medical Center. The pandemic has temporarily restricted her ability to travel regularly to New York for patient care, so she is now teaching and mentoring students and residents remotely from Geneva, where her public health role is based as a primary health care technical advisor for the Global Fund to Fight AIDS, Tuberculosis and Malaria.(www.theglobalfund.org)

"I have had good fortune in that Columbia values me both as a clinician and in my role as a public health advocate and the larger work I do in health systems strengthening," she said.

With the Global Fund, Ferenchick's role involves supporting countries' strategic investments in building resilient and sustainable systems for health with an emphasis on strengthening primary care to improve health outcomes for HIV, TB and malaria. Before taking her current role in 2018, she had worked as a long-term consultant not only for the Global Fund but also the World Health Organization and Gavi, the Vaccine Alliance.

Ferenchick will share her insights on working with governments and global health financing institutions, including the Global Fund, during the virtual Global Health Summit Sept. 16-18.

"There are a lot of family physicians interested in global medicine, and they find opportunities for short-term exchange programs or mentoring and teaching roles," she said. "But I don't think many are fully aware of the possibilities of engaging with these larger institutions."

The Global Fund invests more than $4 billion a year to support programs in more than 100 countries. For example, Ferenchick worked on an adolescent health project in the Democratic Republic of the Congo that allowed health care workers to participate in a monthly collaborative learning experience aimed at strengthening their skill sets specific to caring for adolescent patients with respectful and clinically sound care. The Global Fund provided financial resources and technical support for the implementation of the project as part of its larger scope of work on reducing the vulnerability of adolescents, particularly girls and young women, to HIV. The World Health Organization will be conducting an evaluation of the project to assess its impact in the coming months, she said.

Doing such work, Ferenchick said, requires both clinical and public health perspectives.

"Family medicine is very rooted in the principles of people-centered care," she said. "Family physicians have an important voice in steering the direction we invest in both domestic and global health, specifically in primary health care, to meet patients' complex and many needs. COVID-19 has shown us the importance of primary health care and what happens when primary health care systems are weak."

Continue reading here:

Family Medicine Is Key to Her Career in Global Health - AAFP News

The National Academy of Sports Medicine (NASM) and the Athletics and Fitness Association of America (AFAA) Announce All-Virtual 2020 Optima Conference…

Posted on by

"The future of fitness requires adaptability. Taking Optima to an all-virtual format offers an opportunity to connect our community with the tools and knowledge to succeed in this rapidly changing world," said Laurie McCartney, President of NASM and AFAA. "By bringing together the brightest minds in the fitness industry, and using the latest technology, we will connect our trainers and instructors with insights and real-world strategies that will elevate their expertise."

The four-day event includes over 70 educational sessions, guided workouts, and valuable opportunities for the fitness community to network with thought-leaders, sponsors, and exhibitors in a state-of-the-art virtual environment.

Randy Hetrick, the founder of TRX and a former U.S. Navy Seal, will serve as the keynote speaker. As the creator of the versatile and portable TRX suspension training system, Hetrick is a leading pioneer in virtual training.

View original post here:

The National Academy of Sports Medicine (NASM) and the Athletics and Fitness Association of America (AFAA) Announce All-Virtual 2020 Optima Conference...

Alumnus donates $5 million to the Lewis Katz School of Medicine – Temple University News

Posted on by

Renowned cardiac surgeon Gerald M. Lemole, MED 62, and Emily Jane Lemole have established the Lemole Center for Integrated Lymphatics Research at the Lewis Katz School of Medicine with a transformational donation of $5 million.

Temple University is home to world-class research that improves the health and lives of people every day. This very generous gift by Dr. Gerald Lemole and Emily Jane Lemole adds another vital area of research, said Temple University President Richard M. Englert. I am deeply grateful to the Lemoles, and on behalf of everyone at Temple University, want to thank them for their thoughtfulness and generosity.

A part of the immune system, the lymphatic system is a network of organs and nodes that help the body regulate fluid and fight illness.

The Lemole Center will serve as an interdisciplinary hub to further understanding of the lymphatic system and the part it plays in cardiac, neural and vascular diseases. By integrating basic science and clinical research, the center will promote the translation of new knowledge from the laboratory to the bedside, where it can inform patient treatment and care.

We are grateful to the administration of the Lewis Katz School of Medicine and congratulate them for their visionary approach to lymphatics research, which has always been studied adjunctively as an access route for other systems rather than the unifying, facilitating, actively integrated bedrock system that it is, said Lemole.

Led by Michael Autieri, associate director and professor in the Cardiovascular Research Center, the new collaborative center will bring together experts from around the region, nation and world to share scientific breakthroughs.

Since his early days as a doctor, Lemole has been fascinated by the lymphatic system and its role in overall health and wellness. He is the author of many publications on lymphatics for both a professional and general audience, including The Healing Diet: A Total Health Program to Purify Your Lymph System and Reduce the Risk of Heart Disease, Arthritis and Cancer.

In 1968, Lemole was part of the team that performed the first heart transplant in the U.S. The following year, he completed the first coronary bypass in the tri-state area and was named chief of cardiothoracic surgery at Temple. In 1975, at age 38, with his appointment to full professor of surgery at Temple, he became one of the youngest in the country to hold such a position.

Lemole went on to serve as chief of surgery at Deborah Heart and Lung Center in New Jersey, chief of cardiovascular surgery at the Medical Center of Delaware, and medical director at Christiana Cares Preventive Medicine and Rehabilitation Institute and Center for Integrative Health.

Emily Jane Asplundh Lemole is a former trustee of the Fund for West Chester University of Pennsylvania, a former commissioner of Lower Moreland Township, Pennsylvania, and a minister in the Swedenborgian Church of North America.

A combination of Dr. and Mrs. Lemoles forward-looking philanthropy and leadership has led to this watershed moment at the Lewis Katz School of Medicine, said John M. Daly, the Harry C. Donahoo Professor of Surgery and interim dean at Katz. This type of transformative philanthropy shapes institutions and accelerates science.

Long-time friends of the medical school, the couple previously established the Lemole Lecture Series in Integrative Medicine Fund and named the Dr. Gerald M. and Emily Jane Lemole Executive Conference Room at the Medical Education and Research Building.

Dr. and Mrs. Lemole have been an integral part of Temples story for decades, and this extraordinary relationship has led to a transformative philanthropic investment in the Lewis Katz School of Medicine, said Nina Weisbord, chief advancement officer for Temple University Health System and assistant dean at Katz. We are incredibly grateful for their enduring commitment, vision, partnership and support.

Link:

Alumnus donates $5 million to the Lewis Katz School of Medicine - Temple University News

Generations News: Medicine tips and more – Washington Times Herald

Posted on by

QUICK MEDICATION TIP FROM ACTIVE DAILY LIVING: If you use a pill organizer, always keep one or two pills in the original bottle. It can be used to remind you what the pill is. Also, if you drop a pill on the floor, you can match it to the bottle pill, so you know what it is. If you found this quick tip helpful and would like to access more tips like this, please visit the Generations website at http://www.generationsnetwork.org and click on the Active Daily Living link on the home page. Active Daily Living offers FREE, personalized advice to enhance health, independence and aging in place. Here you can access videos, articles and resources that are tailored to your needs on a variety of topics that focus on older adults and caregivers.

GENERATIONS IS LOOKING FOR VOLUNTEERS: We welcome individuals of all ages who want to use their life experience and skills to make a difference in our community, regardless of the amount of time that they have to give. Joining does not require a fee and there are no restrictions based on education, income, age, race, experience, citizenship, gender or disability. We have over 40 active volunteer stations (based on community need) offering a wide variety of assignments in nutrition, education, health care, history, socialization, etc. Want more information? Please contact our office at (812)888-5880 or toll free at (800)742-9002. You may also reach us by e-mail at generations@vinu.edu. Come join us!

INDIANA LAUNCHES BE WELL CRISIS HELPLINE TO SUPPORT HOOSIERS DURING COVID-19 PANDEMIC AND RECOVERY: Counselors and resources now available 24/7 at Indiana 211. The Indiana Family and Social Services Administration has announced the launch of the Be Well Crisis Helpline, a confidential resource available through Indiana 211 that will allow Hoosiers to call and speak with a trained counselor 24/7. The free Be Well Crisis Helpline was established by FSSAs Division of Mental Health and Addiction in direct response to the elevated levels of stress and anxiety Hoosiers are experiencing due to the COVID-19 pandemic. Indiana 211 is a free service that connects Hoosiers with assistance and answers from thousands of health and human service resources across the state quickly, easily and confidentially. Earlier this month, Indiana 211 officially became part of FSSA, helping enable specialized programs such as the Be Well Crisis Helpline as needed. By calling 2-1-1 (and selecting 3), callers will connect with an experienced and compassionate counselor specially trained to help with issues triggered or worsened by COVID-19, said Jay Chaudhary, J.D., DMHA director. The trained counselors will be able to listen, provide support and promote personal resiliency.

The Be Well Crisis Helpline is funded by a Crisis Counseling Assistance and Training Program grant from the Federal Emergency Management Agency. In Indiana the program becomes part of the states new Be Well Indiana initiative. Additional information about the mental health resources available to Hoosiers is available at BeWellIndiana.org.

GENERATIONS MAGAZINE: Our magazine is geared toward adults in pre-retirement and retirement years and promotes active aging and preventive health. It is published three times a year and is free to subscribers. All we need is your name and address. If you would like to receive future copies of the magazine, contact Brenda Hancock at 812-888-5146 or bhancock@vinu.edu.

Generations, Area 13 Agency on Aging & Disability, is a program of Vincennes Universitys Community Services Division. Our agency connects individuals and caregivers to community resources and options for long-term care and in-home services. For more information, call 1-800-742-9002 or 812-888-5880 or visit our website at http://www.generationsnetwork.org

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

Originally posted here:

Generations News: Medicine tips and more - Washington Times Herald

Clugston hopes to cash in on government infrastructure funds – Medicine Hat News

Posted on by

By MO CRANKER on July 31, 2020.

mcranker@medicinehatnews.com

With the province announcing more than $1 billion in funding for provincial municipalities earlier this week, Medicine Hats mayor is hoping to make use of the money.

The funding is a mixture of federal and provincial money and is aimed at building shovel-ready infrastructure projects starting this year. It is also there to help with municipal operating costs during the COVID-19 pandemic and to help support public transportation costs.

I think like every other municipality, well take what we can get, said Mayor Ted Clugston. We dont have the exact number yet, but were about 1.5 or 1.6 per cent of the population of Alberta. We expect to get about $8 million for capital and about $4 million for operating.

Again, we dont have the numbers yet, but those are a rough estimate of what we could be looking at in Medicine Hat.

Clugston says there are a lot of projects that could make use of the added funding.

Theres a number of capital projects that would benefit from this, he said. One I can think of is the water treatment plant upgrades.

On the operation side, weve been running transit at a loss and various other things at losses. Weve had to close down facilities like the leisure centre and the library, and theres been a lot of revenue lost in not having them open.

Were happy and were thankful for this funding.

Clugston hopes to see the money dispersed fairly.

A big concern for me is that Calgary and Edmonton havent looked after their finances as well as Medicine Hat has, he said. I dont think that would be a fair reason for them to get more than their fair share just because theyre in more trouble than we are.

I just hope Medicine Hat is able to get our per-capita amount, hopefully like everyone else does.

Clugston says the city was asked to submit a list of capital projects right at the beginning of the pandemic and that he believes funding is for projects that havent started yet.

I think the province is looking for projects that need some money to get past their tipping point, he said. The best example I have is the water treatment plant, because we need to do more with it and its very expensive.

You must be logged in to post a comment.

Read the original post:

Clugston hopes to cash in on government infrastructure funds - Medicine Hat News

In these times, this comeback win was good medicine for the Red Sox – The Boston Globe

Posted on by

The Sox arrived at Citi Field having lost four consecutive games, their pitching staff in shambles. Two of those losses had come against the Mets at Fenway Park on Monday and Tuesday.

It looked like more of the same when Nate Eovaldi allowed a run in the first inning.

But Eovaldi hung in there against the imposing Jake deGrom and the Sox scored three runs in the eighth inning and held on to steal a 6-5 victory.

One game will not fix the rotation or turn the season around. But one game did prove this team is capable of fighting back and thats where it has to start.

deGrom was throwing triple-digit fastballs and vanishing changeups early in the game, running his streak of scoreless innings to 30 before Rafael Devers and Mitch Moreland had back-to-back doubles in the fourth inning to produce a run.

Moreland then made his way around on two wild pitches, not his usual way to find the plate.

After the Mets took a 3-2 lead in the sixth inning, Christian Vazquez belted a no-doubt home run in the seventh.

It only got more interesting from there. Sox manager Ron Roenicke, the proverbial good guy in a bad spot, went to Josh Osich in the bottom of the seventh. Osich was the opener on Monday and gave up a two-run homer to Michael Conforto, who was due up fourth in the inning.

When two hitters reached, it looked like a mistake. But Osich got Conforto to ground out. Heath Hembree then came in and struck out pinch hitter J.D. Davis on three pitches.

Roenicke continued to push buttons in the eighth inning. He pinch hit Kevin Pillar for Jackie Bradley Jr. against lefty Justin Wilson.

Pillar reached on a bloop single. Xander Bogaerts, who was too banged up to start, pinch hit and drew a walk. He also was too sore to run and Jonathan Arauz replaced him at first base.

(Who is that, you ask? Arauz is a 21-year-old Rule 5 pick from Houston.)

Andrew Benintendi, who to that point was 1 for 18 this season, put down a sacrifice bunt. The Mets intentionally walked J.D. Martinez to load the bases and Wilson struck out Devers.

Roenicke stuck with Moreland against a lefty and he drove in a run with a swinging bunt. When Vazquez poked a single to right, the Sox had a 6-3 lead.

Matt Barnes allowed a home run by Yoenis Cespedes leading off the bottom of the eighth inning before Robinson Cano singled. But he escaped further trouble when Jose Peraza started a double play that Arauz confidently turned with his bare hand.

Brandon Workman, in his first save situation of the season, loaded the bases with no outs. But he allowed only one run, somehow surviving a 30-pitch inning by getting Cano on a soft liner to end a game that lasted three hours and 44 minutes.

[Workman] was sweating a lot but he managed to get the job done, Vazquez said.

Roenicke acknowledged he managed the game with a sense of urgency, trying to find every advantage he could. In a 60-game season, a 1-4 start was essentially an emergency.

We need to do what we can to win some games, Roenicke said. Get that good feeling back, guys will relax and well start playing better baseball. Whatever we could do I felt we needed to do.

After a month of practicing and playing at Fenway Park, Roenicke and several of the players suggested that a new location helped. But there also was a definite sense that enough was enough after the bad homestand.

This one was big for us, Eovaldi said. Hopefully it gets the ball rolling.

Peter Abraham can be reached at peter.abraham@globe.com. Follow him on Twitter @PeteAbe.

Continued here:

In these times, this comeback win was good medicine for the Red Sox - The Boston Globe

WVU Medicine hospitals earn recognition through U.S. News & World Report – Cumberland Times-News

Posted on by

MORGANTOWN, W.Va. Six WVU Medicine hospitals four member hospitals and two managed hospitals have been recognized in U.S. News & World Reports Best Hospitals 2020-21. This years rankings also include the WVU Medicine Urology Programs fourth consecutive national ranking and WVU Medicine J.W. Ruby Memorial Hospitals designation as theNo. 1 hospital in the state.

In addition to urology, which was ranked 40th in the country, Ruby Memorial Hospitals nephrology, neurology and neurosurgery, orthopedics and pulmonology and lung surgery programs were recognized as high performing specialties.

The six WVU Medicine hospitals designated as high performing in the procedures and conditions category are Berkeley Medical Center, Camden Clark Medical Center,Ruby Memorial,Uniontown Hospital, United Hospital Center andWheeling Hospital.

We are thrilled to have more specialties and more hospitals recognized by U.S. News and World Report. These rankings validate the strides we have made in strengthening our system and the care we provide throughout it, Albert L. Wright Jr., president and CEO of the West Virginia University Health System, said. Of course, none of this would be possible without the hard work and dedication of our employees, and we thank them for making WVU Medicine the world-class health care system that it is.

The annual Best Hospitals rankings and ratings, now in the 31st year, are designed to assist patients and their doctors in making informed decisions about where to receive care for challenging health conditions or for common elective procedures.

For the 2020-21 rankings and ratings, U.S. News evaluated more than 4,500 medical centers nationwide in 26 specialties, 10 procedures and conditions. In the 16 specialty areas, 134 hospitals were ranked in at least one specialty. In rankings by state and metro area, U.S. News recognized best regional hospitals based on high performing rankings across multiple areas of care.

For more than 30 years, U.S. News & World Report has been helping patients, along with the help of their physicians, identify the best hospitals in an array of specialties, procedures and conditions, said Ben Harder, managing editor and chief of health analysis at U.S. News. The hospitals that rise to the top of our rankings and ratings have deep medical expertise and each has built a track record of delivering good outcomes for patients.

The U.S. News Best Hospitals methodologies in most areas of care are based largely on objective measures such as risk-adjusted survival and discharge-to-home rates, volume and quality of nursing, among other care-related indicators.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

The rest is here:

WVU Medicine hospitals earn recognition through U.S. News & World Report - Cumberland Times-News

INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP) -…

Posted on by

PLYMOUTH MEETING, Pennsylvania, July 29, 2020 /PRNewswire/ --INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (RRP).

RRP is a rare disease caused by human papillomavirus (HPV) types 6 and 11 infections. RRP causes noncancerous tumor growths leading to life-threatening airway obstructions and can progress to cancer in rare cases. Currently, the disease is incurable and is mostly treated by surgery to remove the tumor growths to temporarily restore the airway. The tumor almost always recurs and the surgery must be repeated, often multiple times a year. RRP can severely impact the quality of life for those living with the disease.

Orphan drug designation is intended to advance drug development for rare diseases. FDA grants orphan drug status to medicines intended for the prevention, diagnosis, and treatment of rare diseases or conditions. In the United States, an orphan disease is defined as a disease or condition with a prevalence of less than 200,000 patients in the United States annually. This orphan drug designation from the FDA qualifies INO-3107 for various development incentives, including a tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, research grant awarded by the FDA, and most importantly, 7 years of U.S. market exclusivity upon approval for the treatment of RRP.

Ami Shah Brown, Ph.D., MPH, INOVIO's Senior Vice President, Regulatory Affairs, said, "Receiving FDA's orphan drug designation for INO-3107 is an important milestone in the development of INOVIO's DNA medicine for this rare disease and clearly underscores the importance of addressing the unmet medical need for this debilitating condition."

The open-label, multicenter INO-3107 Phase 1/2 trial is currently open to enrollment to recruit 63 subjects in the U.S. and will evaluate the efficacy, safety, tolerability, and immunogenicity of INO-3107 in subjects with HPV 6 and/or 11-associated RRP who have required at least two surgical interventions per year for the past three years for the removal of associated papilloma(s). For this study, adult subjects will first undergo surgical removal of their papilloma(s) and then receive four doses of INO-3107, one every three weeks. The primary efficacy endpoint will be a doubling or more in the time between surgical interventions following the first dose of INO-3107 relative to the frequency prior to study therapy.

Last year, INOVIO published data from its pilot clinical study of INO-3106 (DNA medicine candidate targeting HPV 6-caused RRP) in the scientific journal Vaccines (MDPI). Study results demonstrated that INO-3106 generated immunogenicity and engagement and expansion of an HPV 6-specific cellular response, including cytotoxic T cells. The paper also showed that INOVIO's immunotherapy allowed two out of two patients who previously required approximately two surgeries per year for several years to manage this disease to delay the need for surgery to a robust degree; one patient was able to delay surgery for over a year and a half (584 days surgery-free) and a second remained surgery-free for over two and a half years (over 915 days surgery-free).

About RRP

Recurrent respiratory papillomatosis (RRP) is a rare disease (estimated at 15,000 active cases in the U.S.) that is characterized by the growth of tumors in the respiratory tract caused by the human papillomavirus. Although benign, papillomas can cause severe, even life-threatening airway obstruction and respiratory complications. A distinguishing aspect of this disease is the tendency for the papilloma to recur after surgical procedures to remove them. Left untreated, if RRP develops in the lungs, affected individuals can potentially experience recurrent pneumonia, chronic lung disease (bronchiectasis) and, ultimately, progressive pulmonary failure. In rare cases papillomas can become cancerous (malignant transformation) developing into squamous cell carcinoma. Additional symptoms of RRP can include hoarse voice, difficulty in sleeping and swallowing, and chronic coughing. RRP symptoms are usually more severe in children than in adults. In children, the disorder is most often diagnosed at or around the age of four years. In adults, the disorder occurs most often in the third or fourth decade.

Story continues

About INOVIO's DNA Medicines Platform

INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with MERS and COVID-19 diseases being developed under grants from the Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S. Department of Defense. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.

INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA. The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA device ensures that the DNA medicine is efficiently delivered directly into the body's cells, where it can go to work to drive an immune response. INOVIO's DNA medicines do not interfere with or change in any way an individual's own DNA. The advantages of INOVIO's DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, safety profile, and tolerability that have been demonstrated in clinical trials.

With more than 2,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs.

About INOVIO

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DOD), GeneOne Life Science/VGXI, HIV Vaccines Trial Network, International Vaccine Institute (IVI), Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. For more information, visit http://www.inovio.com.

CONTACTS:

Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.comInvestors: Ben Matone, 484-362-0076, ben.matone@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop DNA medicines, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical studiesand clinical trials, and the availability and timing of data from those studies and trials. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals andother factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

SOURCE INOVIO Pharmaceuticals, Inc.

See the rest here:

INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP) -...

Elon Musk selling LA homes and dreams of move to ‘self-sustaining’ Mars colony – Daily Star

Posted on by

Elon Musk is one of the richest people on the planet with a net worth estimated to be in the region of $69 billion.

But the tech innovator who founded PayPal, Tesla and SpaceX says hes thinking about becoming homeless.

Hes put two of his mansions up for sale, tweeting in May: I am selling almost all physical possessions. Will own no house.

He added that he would devote his life to Mars and Earth and said he didnt need any more money because possessions just weigh you down.

Now in a wide-ranging New York Times interview he said: I guess well just rent a place somewhere

I just have all these houses but nobody is using them, he said.

I use them infrequently. In the Bay Area, for example from 2002 to 2017, I never owned a house and I was there half the week so I would either sleep at the factory or in a friends spare bedroom or on a couch or in a hotel.

"I did that for 15 years.

Musk joked he could always crash with his fellow billionaires Larry Page and Sergey Brin, the founders of Google.

He says he used to enjoy sofa-surfing with his Silicon Valley pals.

He told the New York Times: It was actually, in retrospect, kind of good because you end up rotating through friends houses and you catch up with them and stay in contact, whereas these days, I have been staying in this strange Gatsby-like house, what I call the haunted mansion, and its a bit bleak, to be totally frank.

The house itself is beautiful but, you know, its like Wayne Manor without Alfred.

Musks focus is increasingly on building a self-sustaining city on Mars, which he says will require 1,000 spacecraft launches a year.

He predicts that the Mars habitat, which will be protected by a huge anti-radiation dome, will have an outdoorsy, fun atmosphere."

He told the Third Row Tesla podcast that there should be a direct democracy on Mars with the inhabitants making decisions for themselves rather than being ruled from Earth.

Musk also says there ought be simpler laws on Mars than there are on Earth.

Food for his first Mars city will be grown on solar-powered hydroponic farms, but Musk says he will probably die before the colony is completely self-sustaining but, he says, Id like to at least be around to see a bunch of ships land on Mars.

See the article here:

Elon Musk selling LA homes and dreams of move to 'self-sustaining' Mars colony - Daily Star

To infinity and beyond: Sex dolls in space could be a reality for Mars 2024 mission – IOL

Posted on by

By Lifestyle Reporter Jul 30, 2020

Share this article:

SpaceX founder Elon Musk must get lots of unusual requests but this one is probably the most bizarre.

The industry titan is on a mission to colonise Mars, something he hopes to achieve by 2024. So what former aerospace engineer Amit Stevenson offered was to provide SpaceX astronauts with some intimate company in the form of sex dolls.

Stevenson, who owns Sex Doll Genie said the the journey to Mars will be lonely work and the company's robotic companions could keep Mars colonists company - rather than just sex, Express reported.

"The purpose of wanting to send companion dolls to space is not sex most of our customers use love dolls to feel accompanied in lonely situations, Stevenson told the British publication.

"This isnt about cheapening the profession of astronauts or space exploration in general, he continued.

A one-way trip to Mars can take between six to eight months - thats a lot of time to spend away from your loved ones.

Dr Nick Kanas, an Emeritus Professor of Psychiatry at the University of California, discussed the psychological implications of this at length in 2018.

"Mars is a long way away and the extreme distance has psychological ramifications, he said.

Stevenson used this argument by suggesting some of the anxiety and psychological stress of these missions can be alleviated with the aid of sex dolls.

Read the original here:

To infinity and beyond: Sex dolls in space could be a reality for Mars 2024 mission - IOL

Nuclear power plants could power colonies on the Moon and Mars – SlashGear

Posted on by

One of the challenges of prolonged presence on the moon or the surface of another planet, such as Mars, is finding the power needed to make human life possible. NASA is reportedly considering building nuclear power plants that will work on the moon and Mars. On Friday, NASA put out a request for ideas from the private sector on how nuclear power could be used outside the Earth in the future.

All ideas submitted from the private sector will be reviewed by the Idaho National Laboratory, which is a nuclear research facility in eastern Idaho, the Energy Department, and NASA will evaluate all submitted ideas for the reactor. NASA says that small nuclear reactors can provide all the power capability needed for space exploration missions.

An industry technical meeting will be held in August to discuss the expectations for the program. The meeting will be conducted by The Energy Department, NASA, and Battelle Energy Alliance. The latter is the contractor that manages the Idaho National Laboratory.

The plan is dual phased with the first to develop a reactor design. The second is to build a test reactor along with a second reactor to be sent to the moon. The program also requires the development of a flight system and lander that can transport the reactor to the moon.

NASA wants the reactor, flight system, and lander ready to launch by the end of 2026. The reactor is required to generate an uninterrupted energy output of at least 10 kilowatts and weighs less than 7,700 pounds. It also has to run for at least ten years and be mostly autonomous. Ten kilowatts isnt much power; the average home in the US uses 11,000 kilowatt-hours per year of electricity. NASA has stated that it would likely take multiple linked reactors to meet power demands on the moon or Mars.

More:

Nuclear power plants could power colonies on the Moon and Mars - SlashGear

NASA To Use Nuclear Power Can Help Colonize Moon And Mars. Is It Worth It? – Inventiva

Posted on by

Nuclear power to be harnessed for future endeavors to Mars and the Moon. On Friday, the U.S Department of Energy put out a request to the private sector, on how this can be accomplished to help humans live for long periods in the harsh environment of space.

How it began?

Exploration of space has become a race for countries to excel at. It reached its peak during the Cold War where the USSR and USA battled to gain the upper hand with the best technology and equipment to conquer space, which is the only area left for humans to expand out territorially. During such times, the space race picked for the superpowers to show off their technological achievements.

There was a great revolution in the field of Aerospace and major improvements in the technological abilities of Man-Made Spacecraft and satellites. This was also the time where nuclear energy was wildly considered to be used for space exploration.

Nuclear energy seemed to be the best option due to its ability to create large amounts of energy from small distortions in the molecular level. However, due to negative reactions from the public because of the various accidents and its major effects on lives and environment. It has always been deemed not worth risking and projects of such systems have been shunt upon.

Is it better than solar?

Solar Energy was considered the best source of energy to power a spacecraft and is more commonly used. However, Nuclear Power offers advantages in few areas that Solar energy cannot comply with. Solar cells are efficient but can supply the energy sufficiently high only during a solar flux, meaning the closer it is to the sun the better energy can be supplied. But space is dark, cold and non-resourceful. Most of the explorations dive into deep space where there is minimal to no light available. And Mars being further away from the sun makes it receive lesser solar energy from the sun, making it all the more difficult to power systems using solar panels.

This is where nuclear-based systems are handy, where it has less mass than solar cells of equivalent power and is independent in its power production. It can also provide with both life support and propulsion to the system and may reduce both cost and flight time.

Why has the usage of Nuclear Power in Space revived?

Nuclear power systems have been launched several times to reach space. One of the earliest and first satellites launched into earths orbit was Transit-4A in 1961 which used 238 Pu (Plutonium-238) as fuel in the RTG SNAP-3B Technology.

So, the usage of nuclear power in space has always been lingered and been used to launch satellites but now NASA has accelerated it plans to send astronauts to the moon by 2024 and by 2028 they plan to establish a sustainable lunar exploration. As is the case, NASA wants to accomplish all of this in the most efficient process and nuclear energy has proven itself over time. Now, to further explore alternatives, it is common for NASA to keep competitions or send request to other private sectors.

Because of this approach and the closing of the moon landing. It has increased the interest of millions to know how NASA plans to accomplish yet another small step for a man, a giant leap for mankind.

How do they plan on using nuclear power?

The plan can be devised into two phases. First, the design of a reactor is to be developed. Second, a test reactor is to be build and a second reactor to be sent to the moon. Also, development of a flight system and lander to transport the reactor to the moon will be underway.

Request has been sent to the private sector by the Energy Department and NASA on the development of nuclear power systems. The ideas will be evaluated by the Idaho National Laboratory, a nuclear research facility in eastern Idaho. They all plan to have webcast technical meeting in August concerning the programs expectations.

As of now, the reactor to be used must be able to generate uninterrupted electricity output of at least 10 Kilowatts. Compared to an average residential home in U.S.A, where 11,000 Kilowatts-hour per year is consumed. Additionally, the reactor should not weigh more than 3,500 kg and function autonomously in space for at least 10 years.

Exploration has been supported to revolve around the south polar region of the moon while the exploration for the Martian surface has not been identified.

How will it work?

Nuclear power in space has been around since the 1950s as mentioned earlier. Now, it can be segregated in the form of systems such as, small fission systems or radioactive decay for electricity or heat. Several space probes and crewed lunar missions have most commonly used the Radioisotope Thermoelectric Generator(RTG).

To generate power, a power-conversion unit consisting of two Stirling engines will be made to sit opposite each other. The set up for the testing was at NASAs Marshall Space Flight Center. Electricity was generated when the pumped liquid metal transfers heat from the reactor to the engine.

Researchers have tested the performance of the Stirling alternator in a radiation environment at Sandia national laboratories in Albuquerque, NM. The main aim was to test the performance of the motor without degradation of the materials. The alternator was tested by subjecting it to radiations 20 times than what it could expect in its lifetime. It survived the whole test without any significant problems.

So far, the reports have pointed that one of the concepts in technology of testing a power source for missions to the moon and mars could be deployed by 2020. But has been slowed down due to the COVID-19 outbreak.

Fission systems have been effective in reducing cost compared to the RTGs, where it can be utilized to power the spacecrafts heating or propulsion systems. Several fission reactors have been proposed over decades, which makes fission reactors the closest choice for the next nuclear power system advancement.

Why use nuclear systems?

As discussed previously, why nuclear systems would fare better than solar panels. There are countless other reasons to why humanity can lend its trust in nuclear technology to help boost the accomplishment in colonizing the moon and mars.

Radioisotope Thermoelectric Generator (RTG) has been the basic generator device used in most of the space missions. It is prominently well protected and can sustain even during malfunctions. When the Nimbus B (a meteorological satellite) was launched, it malfunctioned in the booster guidance system and never reached the orbit. The spacecraft was destroyed but the SNAP-19 RTG was salvaged from the water, refurbished and later flown on Nimbus 3, which was a success.

This comes to show that not only can they sustain damages but are capable of being used again for future endeavor, making them more reliable than other sources of power.

Space is unforgiving and requires the upmost advantage while traversing through space. For that, the following reasons prove why nuclear power in space is beneficial:

Nuclear energy benefits the few, not the many. This is true when considering the fact that the nuclear power system will demand lots of expenses and have large risks every step of the way.

Especially, when huge power is generated, the nuclear power system produces comparatively more nuclear waste that could harm and cause hazardous effects for the people involved. Even though researchers have stated that the nuclear waste will be buried far away from the designated sites of the astronauts. The data however, gives an unsettling reminder of how nuclear waste has been dangerously hazardous and still can be potentially deadly with its radiation for thousands of years.

The Chernobyl incident is estimated to have caused around 10,000 deaths and also has left a long-term effect of radiation in the area. With such concerns, it is quietly nature to object the use of nuclear power systems. What good can it be when it could potentially radiate the surrounding with harmful radiation and make it even more uninhabitable than it already is.

Humans have conquered every inch of this earth one step at a time. By conquering the land with vehicles on roads and railways, with ships and submarines in/on water, the air with aircraftsand drones and now the space with satellites and spacecrafts, to soon be able to create colonies and settle in other worlds. These technological achievements of man are what drives them to be better and evolves them to do better than before.

Nuclear technology has its pros and cons, but overall every technology faces that. If NASA is capable of accomplishing the next big leap for human space exploration and nuclear is one way that can help them. Then, finding the best and most effective ways to carry it out without the risk of endangering the planet or other life forms is crucial.

Like Loading...

Related

Read more from the original source:

NASA To Use Nuclear Power Can Help Colonize Moon And Mars. Is It Worth It? - Inventiva

Mold grown in Chernobyl may protect astronauts from radiation in space – Business Insider – Business Insider

Posted on by

Astronauts take many risks in space, but exposing themselves to dangerous radiation is one of the biggest. On the International Space Station, astronauts are exposed to up to 160 millisieverts of radiation during a six-month mission, according to NASA, that's about 1,600 chest x-rays, and 26 times more than the average US citizen receives. Mars is even worse; an astronaut making an 18-month round trip to the red planet would be exposed to 1,000 millisieverts of radiation, or 10,000 chest x-rays' worth.

For protection, astronauts generally rely on radiation shields made of plastics or metals like aluminum and stainless steel. But these can be heavy and vulnerable to damage.

So in 2018, some high school students from Durham County, North Carolina proposed an unusual solution to this problem: Make a shield out of mold.

Specifically, they suggested cladosporium sphaerospermum, an organism that appears to feed on nuclear radiation the same way most plants feed on sunlight. The mold has thrived in Chernobyl's exclusion zone, the site of the 1986 nuclear meltdown, which is still one of the most radioactive places on Earth.

The students, led by Graham Shunk, now an incoming second-year student at the North Carolina School of Science and Mathematics, obtained samples of the mold species from a company in Minnesota. With the help of the research company Space Tango, they blasted them into outer space in December 2018.

On the International Space Station, astronauts put the mold samples into Petri dishes, leaving one side of each dish empty. Geiger counters then measured radiation levels beneath the dishes every 110 seconds for 30 days. The results showed that radiation levels decreased at the height of the mold's growth: The counters measured a 2.4% decrease in average radiation levels beneath the mold-covered sides.

Researchers grew Cladosporium sphaerospermum mold on the left sides of petri dishes on the International Space Station. Space Tango, Inc.

The preliminary findings from that experiment were uploaded to the research archive bioRxiv on July 17, but have not yet been peer-reviewed. Still, they suggest that the mold could act as a shield against radiation in space.

That's because the mold appears to absorb radiation and convert it into chemical energy in a process called radiosynthesis. It's similar to photosynthesis, the process most plants use to convert sunlight into energy.

Shunk and the other researchers suggested that if the mold were about 21 centimeters thick, it could provide humans adequate protection from radiation levels on Mars. The protection would be stronger if the mold surrounded an object entirely, they think, instead of just shielding one side as it did in the study.

The International Space Station orbits Earth. NASA

The mold has a big advantage over other types of radiation shields, the researchers also noted, since it can grow and replenish itself in space. That means a microscopic amount of C. sphaerospermum could be all that's needed at the start of a launch so it wouldn't add extra weight to a rocket. That could be a game-changer, since NASA estimates that launching something into space costs about $10,000 per pound.

Go here to read the rest:

Mold grown in Chernobyl may protect astronauts from radiation in space - Business Insider - Business Insider

We Are In The Golden Age Of Fraud – Gold Seek

Posted on by

Elon Musk has personified the hopes and dreams of this bull market; Tesla burnishes its results through aggressive accounting; its a culture of deception because it is selling self-driving, which doesnt yet exist. Jim Chanos from We Are In The Golden Age Of Fraud (Financial Times)

Jim Chanos is perhaps the most well-known remaining short-seller in this market. Dont be fooled by his demure characterization of Elon Musk and Tesla. Its calculated diplomacy. The numbers are far more than just polished up to look good the accounting is not just aggressive, its fraudulent, and Chanos knows that as well as anyone.

Chanos describes the current environment as a really fertile field for people to play fast and loose with the truth, and for corporate wrongdoers to get away with it for a long time. He reels off why: a 10-year bull market driven by central bank intervention; a level of retail participation in the markets reminiscent of the end of the dotcom boom; Trumpian post-truth in politics, where my facts are your fake news; and Silicon Valleys fake it until you make it culture, which is compounded by Fomo the fear of missing out. All of this is exacerbated by lax oversight. Financial regulators and law enforcement, he says, are the financial archaeologists they will tell you after the company has collapsed what the problem was. (Financial Times)

I have said many times that Tesla and Elon Musk embody and reflect the extreme degree to which the U.S. system has defined deviance downward into what is now a complete Banana Republic controlled by crony-capitalist elitists who are putting the screws to the middle class. The money printed by the Fed is nothing more than the thinly veiled bailout of the biggest banks nothing more effecting the greatest wealth transfer in history.

The fraud and corruption is blatant. And theres nothing the masses can do about it at this point. The U.S. economic, financial, political and legal system is now amalgam of 1984 and Atlas Shrugged. Eventual collapse is fait accompli.

Chanos himselfburnishesthe adjectives he uses to convey the degree to which the U.S. system has been engulfed in fraud, corruption and open theft. In my opinion, Francisco DAnconia in Atlas Shrugged describes the U.S. perfectly in this excerpt from the famous Money Speech:

Watch money. Money is the barometer of a societys virtue. When you see that trading is done, not by consent, but by compulsionwhen you see that in order to produce, you need to obtain permission from men who produce nothingwhen you see that money is flowing to those who deal, not in goods, but in favorswhen you see that men get richer by graft and by pull than by work, and your laws dont protect you against them, but protect them against youwhen you see corruption being rewarded and honesty becoming a self-sacrificeyou may know that your society is doomed.

Read more here:

We Are In The Golden Age Of Fraud - Gold Seek

Free drugs is the answer to problems | Opinion – pentictonherald.ca

Posted on by

Using our brains, humanity has survived ice ages, the dark ages and the stone. We lived by our wits and our grit on our never-ending march towards enlightenment.

Its been a long damned rocky road, and as I look around, and flick the channels I see stupidity on a global scale.

Ants are better organized than our brightest politicians (oxymorons). Humans are making a bigger mess of our planet than a herd of elephants on ex-lax.

The virus hit the rich and poor alike well thats not reality-true the rich can afford to stay at home and door-dash. The poorest are the homeless, the mentally challenged and the drug addicted, and in most cases all three at the same time.

If we as a society dont acknowledge and care for these unfortunate human beings; the illness we now cower from, will remain like a hot ember in dry grass.

But out of the gloom came a bright idea from Dr. Bonnie Henry a glimpse of light at the end of the tunnel.

She said we should stop the spread of disease and death, by extinguishing the virus for all of our citizens. To do this, her idea not only had to be brilliant, it had to make economic sense as well.

The idea: free drugs.

Would you like to be a drug addict? Would you like to wake up with the sweats, shaking and your body aching until you push that needle into your vein sounds like fun, eh?

You can trust me when I say, shooting heroin feels like someone just poured a bucket of warm pleasure over you. Back in my rock and roll days; it was sex, drugs and rock and roll.

I was lucky enough to hit rock bottom and come up for air a lot of my drug buddies didnt get the choice death took them much too young.

But back to our hero Dr. Bonnie, and her ray of enlightenment.

I want you to think of the time some jerk ripped you off; did you get mad and feel violated? If the fuzz did anything more than fill out a report, youre lucky, and if they did recover your property you should buy a lottery ticket.

Stolen goods are a big racket, and like all successful businesses, repeat business is the key. When druggies need a fix, theyll do anything; theyd steal Jesus off the cross and go back for the nails.

Free drugs would solve that.

Clean shooting galleries with safe zones to zone-out, and eventually theyll change their minds even junkies dont want to be junkies.

The light at the end of the tunnel would be to eliminate diseases of all kinds, take the money away from crime and put it back into taxpayers pockets.

If the keystone cops cant stop the war on drugs maybe the money could be better spent fighting societies real villains: poverty, mental issues and drug addiction.

Lets recap: reduces disease, saves some mothers kid from death, prevents some jerk from stealing your stuff, empties courtrooms and jails, takes money from crime and makes common sense.

The war on drugs has cost hundreds of billions of dollars, countless lives and it should anger you that you have funded it for decades.

You know who doesnt like the doctors idea? Idiots, criminals, undertakers and little old ladies who think they live in the 1950s.

Bernie Bates resides in West Kelowna and is a regular contributor to Westside Weekly, a sister publication.

Email: beeinthebonnet@shaw.ca

Originally posted here:

Free drugs is the answer to problems | Opinion - pentictonherald.ca

Defunding the police is a logical way to reduce harm – The CT Mirror

Posted on by

There are 79 towns in Connecticut which dont have municipal police departments. Over half a million Connecticut residents live in towns which either have no dedicated police presence or are serviced by a small cohort of state troopers.

Then there are some cities and towns, like Hartford, New Haven and Bridgeport, that are heavily policed. Cruisers dot the landscape like measles. Beat cops patrol neighborhoods at all hours of the day and surveillance, particularly of poor, Black and Latinx neighborhoods, is constant.

This is such a widely accepted pattern that we rarely stop to think: why? Why is it that New Haven demands such a heavier police presence than Darien? The standard, culturally embedded answer is that these cities have more crime, and that therefore they must be policed. But most people would agree that there is nothing inherently criminal about the residents of New Haven. When a person in New Haven is born, theyre not immediately more prone to larceny or assault.

If you do believe criminality is an inherent trait, by proxy, you believe that Black and Latinx communities are inherently criminal, as they are disproportionately represented in our prisons and jails. This is a fundamentally racist worldview.

If criminality isnt inherent, that must mean it is a product of social conditions. The root cause of most crime is desperation, which is in turn caused by systemic, generational poverty. Cities, like New Haven, that have more crime are also cities with high rates of poverty. Crime that is not necessarily rooted in desperation, like sexual assault, can still be traced to fixable social problems. In the case of sexual assault, the problem is deeply rooted patriarchy which teaches men predatory behavior. These are difficult problems to deal with, but they are also problems which the police do nothing to address.

But those in power, by imposing unequal patterns of policing, do imply that there are certain populations which are naturally criminal, and therefore must be policed, controlled and contained, rather than provided with the social services that would solve underlying social problems. While it is tempting to reduce this unequal governance to individual bias, it is more accurate to trace these racialized ideas of criminality through their history.

Criminality is a socially constructed idea, and what is considered a crime is almost always driven by a social goal, which is almost always racialized. After the Civil War ended slavery, states were quick to create black codes, which targeted formerly-enslaved Black communities for crimes such as vagrancy. The newly-freed Black population quickly became a newly-incarcerated population, forced to work for free once again. Legal segregation and Jim Crow laws criminalized being Black in America. The war on drugs was a means of incarcerating Black communities (Nixon, and other politicians, stated as much in private). On and on and on.

Its also important to distinguish between the idea of harm and our socially constructed idea of crime. We often associate crime with harm, but these two ideas are distinct. There are many actions which are both not harmful and criminalized, like sleeping on a park bench or sex work. There are also many actions which are harmful and not criminalized, like a landlord evicting a tenant in the middle of a pandemic or a CEO stealing the value his workers produce.

In Connecticut, essentially all of our legislators accept the culturally dominant and deeply racist narrative that certain populations are criminal and need to be policed, while other populations do not. This pattern of policing is a violent imposition on Black and Latinx communities. Jayson Negron, Mubarak Soulemane and Anthony Jose Chulo Vega Cruz are just a few victims of this imposition.

Organizers calls to defund the police are a recognition of this racist and ineffective pattern of policing. If we want to build strong, healthy communities, we need to invest in the root causes of harm like lack of housing, unaffordable healthcare, low wages, unemployment, poor public transportation, low-quality education, unaddressed mental illness, generational trauma and embedded cultural norms.

Defunding and abolishing the police is not rooted in a desire to sow chaos or leave our communities vulnerable to violence, as so many detractors claim. We want to invest in fostering community, building accountability and preventing harm before it occurs. As the abolitionist scholar Ruth Wilson Gilmore says: Abolition is about presence, not absence. Its about building life-affirming institutions.

Harry Zehner is a writer, student, researcher and organizer in New Haven.

CTViewpoints welcomes rebuttal or opposing views to this and all its commentaries. Read our guidelines andsubmit your commentary here.

See the rest here:

Defunding the police is a logical way to reduce harm - The CT Mirror

Ease restrictions on medical psychedelics to aid research, experts say – The Guardian

Posted on by

Potential treatments for severe depression, addiction and other mental health disorders are being held up by excessive restrictions on psilocybin, the active ingredient in magic mushrooms, scientists and politicians have said.

Clinical trials suggest that psilocybin may be a safe and effective medicine for patients with certain psychiatric illnesses who do not respond to talking therapies, antidepressants and other drugs. But researchers say their work is being stymied by the government placing the strictest possible controls on the chemical compound.

In a report published on Monday, the Adam Smith Institute, a free market thinktank, and the Conservative drug policy reform group, urge ministers to order a review of psilocybin and remove the obstacles faced by researchers.

Under Home Office regulations, psilocybin is classified as a schedule 1 drug, along with raw opium, LSD, ecstasy and cannabis, and is not considered a medicinal compound. While clinical trials are allowed under licence, obtaining one takes more time and money than many researchers can afford, the authors say.

The report calls on government to make psilocybin a schedule 2 drug, a move that would dramatically cut the cost and time taken to obtain a licence and remove the stigma surrounding research into the drug.

Jo Neill, a co-author on the report and professor of psychopharmacology at Manchester University, said: Patients are losing out because its taking an awful lot longer and its costing a lot more money to get the research evidence we need to have psilocybin approved for use. And there are patients dying in the meantime, there are people killing themselves.

There are people who would be doing this research who arent because they cant afford it and they know its going to take them a year to get the licence. They cannot wait that long. If psilocybin were rescheduled, all the universities would have a programme on this. Its very frustrating.

Early trials suggest that one or two doses of psilocybin can lead to an immediate improvement in anxiety and depression, but such trials are often prohibitively expensive. Neill, who is also chair of the medical psychedelics working group for the nonprofit DrugScience, said one trial cost 20,000 because six separate licences at 3,000 each were needed to cover everything from manufacture to dispensing the drug.

We have a huge unmet medical need in psychiatry, she said. There are a lot of good treatments on the NHS, lots of talking therapy, and antidepressants work for some people. But theres a huge amount of people who are just not being treated. We need to heal people and these drugs are healing.

David Nutt, professor of neuropsychopharmacology at Imperial College London, who was not involved in the report, said schedule 1 licenses cost thousands of pounds and took a year or more to get.

Most universities wont pay for them so research is stymied, he said. Schedule 1 status serves no role in stopping recreational use as there has never been diversion from a research lab to street use. Heroin and fentanyl two much more sought-after drugs are schedule 2, so I say let us store our psilocybin alongside them. It will be perfectly safe and much easier as all universities and hospitals are given schedule 2 status free as a right.

Crispin Blunt, the Tory MP for Reigate and chair of the Conservative drug policy reform group, said the schedule 1 classification had led to a scientific blackout lasting nigh on 50 years that precluded new treatments, and with them, the prospect of a better life for millions.

A Home Office spokesperson said: We need to strike the right balance between enabling legitimate research to take place in a secure environment while ensuring that harmful drugs are not misused and do not get into the hands of criminals. The current classification of psilocybin under schedule 1 does not prevent research or clinical trials under a Home Office licence.

Original post:

Ease restrictions on medical psychedelics to aid research, experts say - The Guardian

Totally Out There: Our Top 5 Psychedelic Stocks – RealMoney

Posted on by

As cannabis investors increasingly cross over to the psychedelic side of the aisle, the race is on to see which company will be the leader. One of the biggest players in the space, Atai Life Sciences, remains a private company.

But there are already numerous publicly traded companies for an industry that -- like cannabis -- is still essentially illegal in the U.S.Plus, the jury is out on whether psychedelic treatment companies and psilocybin mushrooms will be legalized.

Having said that, investors are anxious to grab the next penny stock that may be poised to jump on the psychedelic bubble. Most of these companies are only in the beginning stages of working with psychedelics so there is lots of risk to be sure.

The Top 5 psychedelic companies as measured by market cap:

1. Mind Medicine (MMEDF) , whose market cap is at $60 million, like the others is a relative newcomer to the publicly traded arena. The company listed in March and has been racing ahead in its drug development pipeline. The company has moved beyond ketamine and psilocybin mushrooms and has also embraced LSD (lysergic acid diethylamide) as a treatment compound. MindMed as it is called, has begun clinical trials for LSD to treat anxiety and cluster headaches. The company has clinical trials for MDMA (3,4 Methylenedioxymethamphetamine) and DMT (the active ingredient in Ayahuasca). The company's immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. So far Mindmed has spent $3.9 million on research and development and has no product revenue. MindMed has even said it may not generate revenue for several years. Think of MindMed as a typical biotech play, there is no quick revenue turn like a cannabis company.

2. Champignon Brands (SHRMF) logs in at $57 million. The company hasn't traded any Canadian shares since June, as trading was stopped until the company is able to update its disclosure obligations. Theover-the-countershares still trade. Since then it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. A couple of weeks ago, the company issued a statement that said it decided against a new rebranding effort. It also terminated its plan to buy the Wellness Clinic of Orange County. Champignon said it still planned to file a report with regards to acquiring AltMedCapital Corp. by Aug. 27. The company currently specializes in the formulation and end distribution of a suite of mushroom-infused beverage products and it sells Auralite crystals. The acquisitions are an attempt to move into ketamine treatment clinics.

3. Revive Therapeutics (RVVTF) comes in at $31 million. Revive's cannabinoid delivery technology is being advanced to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. The company has been granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis (liver disease) and FDA orphan drug status designation for the use of CBD to treat ischemia and reperfusion injury from organ transplantation. In February, it announced plans to acquire Psilocin Pharma Corp. for $2.75 million. Psilocin has developed production solutions for the active compound Psilocybin. The precisely dosed formulations work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to eventually Food and Drug Administration approval in the treatment ofconditions such as depression, anxiety, bi-polar disorder, bulimia and anorexia. The company also filed an IND for a COVID treatment.

4. Mydecine Innovations Group Inc. (MYCOF) (formerly known as New Leaf Brands) has a market cap of $18.7 million. The company recently announced the acquisition of NeuroPharm Inc. a Canadian-based developer of natural psychedelic-based treatments for mental health disorders in the Canadian and United States veteran communities. That company entered into a collaborative relationship with Leiden University Medical Center of The Netherlands for the initiation of clinical trials. The project, "NeuroPharm Veteran PTSD Research Project," is preparing a type of protocol to be used for a clinical trial for the specific treatment of PTSD in veterans.In June, the company signed a deal with Mindleap Health Inc. to buy MindLeap's Digital Telehealth Platform which is also focused on the psychedelics industry.

5. Numinus Wellness (LKYSF) is listed with a market cap of $18.2 million. Numinus Health Corp acquired Salvation Botanicals, a company that consists of a testing and research laboratory that is licensed by Health Canada to test cannabis and narcotics substances and a cannabis production facility capable of manufacturing extracts, edibles and topicals. In addition, it has a Dealer's License dated Jan. 1and issued to Salvation under the CDSA for possession, processing, sale, sending, transportation and delivery of psilocybin, mescaline, DMT and MDMA. The company has created a Clinical Advisory Council to explore psychedelic treatments, but so far that is the only effort beyond the license that has been made with regards to psychedelics. For the three months ended April 30, the Company had a net loss of $181,653 and no revenue.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider these names to be a small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Read the original here:

Totally Out There: Our Top 5 Psychedelic Stocks - RealMoney

Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness – Canada NewsWire

Posted on by

Numinus provides tailored treatments for clients of one of Canada's largest addiction treatment organizations

VANCOUVER, BC, July 29, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce its partnership with Together We Can Addiction Recovery and Education Society (TWC). TWC is one of Canada's largest addiction treatment organizations, a registered charity, licensed healthcare provider, and an approved Canadian Federal Government service provider for the veterans' community. The partnership has enabled TWC to enhance its mental health and addiction recovery support services with tailored mind/body wellness programs. Numinus's associated wellness clinic is benefitting from the partnership with a dedicated stream of revenue, reinitiated since the clinic's re-opening post-COVID earlier this month. The active service provider partnership is designed to ultimately support psychedelic-assisted therapies when authorized for use in Canada.

One in five Canadians suffer from addiction in any given year, and deaths from the current overdose crisisattributable to opioid and other addictions are growing. Numinus and TWC share the view that new solutions and integrative approaches are needed to enhance traditional recovery-based approaches to help people make transformative change, heal, and be well. The partnership currently extends the continuum of care provided to TWC clients with specialized mind/body programs which include modalities such as naturopathy, registered massage therapy, trauma and somatic therapies, and breathwork through Numinus's associated wellness clinic in Vancouver. Individualized programs are continually being developed for TWC clients, including Canadian Forces members and veterans dealing with addiction, PTSD, anxiety, grief and loss, and other diagnoses.

Says Brett S., a TWC client who has already benefited from the partnership, "While I was in treatment at Together We Can for my drug addiction, I was given the opportunity to try out the services of the clinic. They not only supported me through recovery from my addictions but also helped me address my ADHD. I'm so grateful that Numinus's services were part of my overall recovery."

Longer term, the partnership also aims to provide TWC clients early-access to safe, evidence-based, regulated psychedelic-assisted therapies through Numinus's implementation science partnerships and to provide Numinus with a key partner when it is able to provide these therapies in addition to its current services.

Although psychedelic-assisted therapies are not yet available outside of a research context, both parties are optimistic these therapies hold great promise as new treatment options for addiction and mental health care and that they will become increasingly accessible through regulatory approvals. A growing body of evidence suggests psychedelics, especially psilocybin, may dramatically improve outcomes from substance use disorders.While more research is required to fully define the outcomes and safety of the therapeutic use of psychedelic substances, the Canadian federal government is under increasing pressure to provide access to psilocybin-assisted therapy for various mental health and addiction conditions.

"The partnership with Numinus is so important for our clients. There is more demand than we can manage for our services, and our clients need the complementary programs Numinus provides," says Stacy Wilson, TWC Executive Director. "We are excited to find a partner that is aligned with our mission and to work with a team that is driven by heartfelt passion. We both believe whole body/mind integrated support is critical to recovery, and we are optimistic that psychedelic-assisted therapies will also play a significant role in addressing addiction recovery when they are regulated."

Adds Numinus Chief Medical Officer, Dr. Evan Wood, an internationally recognized clinician scientist and expert in addiction treatment, "The growing body of research into the role of psychedelic-assisted therapy in the treatment of substance use disorders is incredibly compelling. This partnership creates a wonderful opportunity to consolidate new strategies with an implementation science lens that can ultimately improve safe access to those seeking additional strategies for treatment and recovery."

About NuminusNuminus is a Vancouver-based health care company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies. Numinus's ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health. Each unit is undertaking distinct, synergistic initiatives to hasten approved access to psychedelic-assisted therapy models in Canada and position Numinus as a trusted industry leader for the eventual regulated rollout of these therapies once available. Numinus Bioscience includes a 7,000 square foot research and testing laboratory as well as numerous Health Canada licenses (through its wholly-owned subsidiary Salvation Botanicals), including a cannabis testing license which provides established and growing revenue. It is also a late-stage application for cannabis processing. Additionally, the Company holds a dealer's licence which allows it to import, export, possess, and test MDMA, psilocybin, psilocin, DMT, and mescaline, and it is the only publicly listed company in Canada to be issued a Health Canada license to produce and extract psilocybin from mushrooms for the purpose of developing proprietary extraction methods. These licences will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus R&D leverages established relationships to position the Company for partnerships to host studies, develop medical and therapeutic protocols, and influence regulatory approval. Numinus Health, with one clinic already prototyping systems for efficiency and profitability, is dedicated to delivering therapies that enhance and supplement existing optionscentred around psychedelic-assisted therapies when and where regulatedfor people wanting lasting physical, mental, and emotional health. For more information, visit http://www.numinus.ca.

About TWCFounded in 1993 and located in both Metro Vancouver and Vancouver Island, Together We Can Addiction Recovery & Education Society is one of Canada's premier treatment centres for men battling alcohol and drug addiction. Its mission is to educate and support individuals and their families who desire a new life in recovery. It provides over 310 individuals with an immersive 60-90 day recovery-based primary addiction treatment experience, followed by transitional housing in a therapeutic residential environment. For more information, visit http://www.twcrecoverylife.org.

Forward Looking StatementsThis news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company's facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company's limited operating history and lack of historical profits; reliance on management; the Company's requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

SOURCE Numinus Wellness Inc.

For further information: Dana Harvey, VP Communications and Investor Relations, Numinus, [emailprotected], 778-929-3262; Daniel Maceachern, Operations Manager, TWC, [emailprotected], (604) 451-9854

https://numinus.ca/

Go here to see the original:

Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness - Canada NewsWire